Preliminary experience with partial tolerance protocol in small bowel transplantation

National Medical Journal of China

Volumn 89, Issue 38, 2009, Pages 2695-2698

  Li, Yuan Xin ^a   Li, Ning ^a   Li, You Sheng ^a   Ni, Xiao Dong ^a   Li, Min ^a   Wu, Bo ^a   Wang, Jian ^a   Li, Jie Shou ^a  

^a NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

Author keywords

Campath 1H; Graft rejection; Immune tolerance o Immunosuppressive agents; Organ transplantation

Indexed keywords

ALEMTUZUMAB; CANCER ANTIBODY; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE SODIUM SUCCINATE; MONOCLONAL ANTIBODY; TACROLIMUS;

ADULT; ARTICLE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MALE; METHODOLOGY; ORGAN TRANSPLANTATION; SMALL INTESTINE; TRANSPLANTATION; TRANSPLANTATION TOLERANCE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; INTESTINE, SMALL; MALE; METHYLPREDNISOLONE HEMISUCCINATE; ORGAN TRANSPLANTATION; TACROLIMUS; TRANSPLANTATION TOLERANCE; YOUNG ADULT;

EID: 84871405269     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2009.38.010     Document Type: Article

References (12)

1. Abu-Elmagd K, Costa G, Bond GJ, et al. Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance. Transpl Int, 2009, 22: 96-109.
2. 2008, 46: 636-637.
3. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med, 2008, 358: 362-368.
4. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet, 2003, 361: 1502-1510.
5. 2008, 28: 984-987.
6. The U. S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. The 2007 OPTN/SRTR Annual Report: Transplant Data 1997-2006. [2008-06-08]. http://www.optn.org.
7. Ciancio G, Burke G, Gaynor JJ, et al. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immunemonitoring. Transplantation, 2005, 80: 457-465.
8. Jeffiery AB. Annual research report-2007. Immune Tolerance Network. [2008-02-10] http://www.Immunetolerance.org.
9. Selvaggia G, Gaynora, JJ, Moona, J, et al. Analysis of acute cellular rejection episodes in recipients of primary intestinal transplantation: a single center, 11-year experience. Am J Transplant, 2007, 7: 1249-1257.
10. Shapiro R, Ellis D, Tan HP, et al. Alemtuzumab preconditioning with tacrolimus monotherapy in pediatric renal transplantation. Am J transplant, 2007, 7: 2736-2738.
11. Thai NL, Blisard D, Tom K, et al. Pancreas Transplantation under Alemtuzumab (Campath-1 H) and tacrolimus: correlation between low T-cell responses and infection. Transplantation, 2006, 82: 1649-1652.
12. Zeevi A, Britz J, Bentlejewski C, et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transpl Immunol, 2005, 15: 17-24.